Openbookopenbook
Equity
NKTR
+0.0 · +0.00%
USD · NASDAQ

Nektar Therapeutics(NKTR) Stock Analysis | Healthcare

USD --+0.00%
Reward39Moderate
Risk60Medium-High
75%Data
Thin -288% profit margin · Revenue down 9% YoY
Earnings Deterioration
Market Cap:2.48Bn
ⓘ
Reward Rating
39
Moderate
Reward Assessment
75% data coverage
Bottom 5% of stocksView factors
ⓘ
Risk Rating
60
Medium-High
Risk Assessment
6 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on NKTR to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for NKTR, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $144.40.

What is Nektar Therapeutics?

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.

NKTR · Verdict

Limited reward · elevated risk

NKTR has limited near-term tailwinds — cash flow and growth weigh on the model output.

Based on 88% data coverage

NKTR · Verdict

What’s working & what to watch

Watchouts 4

  • Cash flow16/100

    -378% free-cash-flow margin

  • Growth29/100

    Rev -15.7% CAGR · earnings -23.6%

  • Balance sheet30/100

    Current ratio 4.97

  • Profitability32/100

    -297% net margin · -36% ROE

Model-based scoring. For information only — not financial advice.

What is Nektar Therapeutics?

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.48B.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (39)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

PHVSMid Cap / 2.5B market cap
Pharvaris BV
Compare
VRDNMid Cap / 2.5B market cap
Viridian Therapeutics Inc
Compare
KODMid Cap / 2.4B market cap
Kodiak Sciences Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap2.48B
P/E RatioN/A
Dividend YieldN/A
Beta1.157
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
34,470 shares
$182k
0
9-12months
926,198 shares
$1.1M
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.